Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gesine Bug

Showing results (141-150 of 165) with videos related to

Pageof 17
Sort By:
Bone Marrow Transplantation|March 13, 2025
Allogeneic hematopoietic cell transplantation after infection with SARS-CoV-2 during the COVID-19 pandemic: a multicenter retrospective analysisOsama Ahmad, Nicolaus Kröger, Eva Wagner-Drouet, et al.
Annals of Hematology|April 27, 2021
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)Anna Hecht, Julia A Meyer, Johann-Christoph Jann, et al.
Bone Marrow Transplantation|June 25, 2022
Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMTRaynier Devillier, Jacques-Emmanuel Galimard, Myriam Labopin, et al.
Leukemia|June 15, 2026
Allogeneic hematopoietic cell transplantation for T-cell/histiocyte-rich large B-cell lymphoma: An EBMT lymphoma working party studySimon Renders, Maud Ngoya, Laurence de Leval, et al.
Hemasphere|January 26, 2023
Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the Acute Leukemia Working Party of the EBMTAlexandros Spyridonidis, Myriam Labopin, Bipin Savani, et al.
Bone Marrow Transplantation|December 4, 2025
Frequency and impact of somatic co-occurring mutations on post-transplant outcomes in acute myeloid leukemia: a multicenter registry analysis on behalf of the EBMT ALWPAli Bazarbachi, Jacques-Emmanuel Galimard, Iman Abou Dalle, et al.
JAMA Oncology|February 9, 2023
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical TrialMartin Bornhäuser, Christoph Schliemann, Johannes Schetelig, et al.
Haematologica|January 5, 2023
Activity of decitabine combined with all-<i>trans</i> retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)Christoph Rummelt, Olga Grishina, Claudia Schmoor, et al.
Leukemia Research|April 30, 2013
Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic studyFriederike Braulke, Klaus Jung, Julie Schanz, et al.
The Lancet. Oncology|November 17, 2018
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trialUwe Platzbecker, Jan Moritz Middeke, Katja Sockel, et al.
Pageof 17

Showing results (141-150 of 165) with videos related to

Sort By:
Pageof 17
Bone Marrow Transplantation|March 13, 2025
Allogeneic hematopoietic cell transplantation after infection with SARS-CoV-2 during the COVID-19 pandemic: a multicenter retrospective analysisOsama Ahmad, Nicolaus Kröger, Eva Wagner-Drouet, et al.
Annals of Hematology|April 27, 2021
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)Anna Hecht, Julia A Meyer, Johann-Christoph Jann, et al.
Bone Marrow Transplantation|June 25, 2022
Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMTRaynier Devillier, Jacques-Emmanuel Galimard, Myriam Labopin, et al.
Leukemia|June 15, 2026
Allogeneic hematopoietic cell transplantation for T-cell/histiocyte-rich large B-cell lymphoma: An EBMT lymphoma working party studySimon Renders, Maud Ngoya, Laurence de Leval, et al.
Hemasphere|January 26, 2023
Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the Acute Leukemia Working Party of the EBMTAlexandros Spyridonidis, Myriam Labopin, Bipin Savani, et al.
Bone Marrow Transplantation|December 4, 2025
Frequency and impact of somatic co-occurring mutations on post-transplant outcomes in acute myeloid leukemia: a multicenter registry analysis on behalf of the EBMT ALWPAli Bazarbachi, Jacques-Emmanuel Galimard, Iman Abou Dalle, et al.
JAMA Oncology|February 9, 2023
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical TrialMartin Bornhäuser, Christoph Schliemann, Johannes Schetelig, et al.
Haematologica|January 5, 2023
Activity of decitabine combined with all-<i>trans</i> retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)Christoph Rummelt, Olga Grishina, Claudia Schmoor, et al.
Leukemia Research|April 30, 2013
Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic studyFriederike Braulke, Klaus Jung, Julie Schanz, et al.
The Lancet. Oncology|November 17, 2018
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trialUwe Platzbecker, Jan Moritz Middeke, Katja Sockel, et al.
Pageof 17